Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
Lüftner D, Schuetz F, Schneeweiss A, Hartkopf A, Bloch W, Decker T, Uleer C, Stötzer O, Foerster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Kreuzeder J, Guderian G, Fasching PA. Lüftner D, et al. Among authors: foerster f. Int J Cancer. 2024 Jul 1;155(1):128-138. doi: 10.1002/ijc.34912. Epub 2024 Mar 6. Int J Cancer. 2024. PMID: 38447007
Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study.
Mavratzas A, Baek S, Gerber B, Schmidt M, Moebus V, Foerster F, Grischke EM, Fasching P, Strumberg D, Solomayer E, Klare P, Windemuth-Kieselbach C, Hartmann S, Schneeweiss A, Marmé F. Mavratzas A, et al. Among authors: foerster f. Breast. 2019 Jun;45:22-28. doi: 10.1016/j.breast.2019.02.002. Epub 2019 Feb 13. Breast. 2019. PMID: 30822621 Clinical Trial.
Physical activity levels are positively related to progression-free survival and reduced adverse events in advanced ER+ breast cancer.
Zimmer P, Esser T, Lueftner D, Schuetz F, Baumann FT, Rody A, Schneeweiss A, Hartkopf AD, Decker T, Uleer C, Stoetzer OJ, Foerster F, Schmidt M, Mundhenke C, Steindorf K, Tesch H, Jackisch C, Fischer T, Hanson S, Kreuzeder J, Guderian G, Fasching PA, Bloch W. Zimmer P, et al. Among authors: foerster f. BMC Med. 2024 Oct 8;22(1):442. doi: 10.1186/s12916-024-03671-x. BMC Med. 2024. PMID: 39379960 Free PMC article.
Metastatic male breast cancer: a retrospective cohort analysis.
Foerster R, Schroeder L, Foerster F, Wulff V, Schubotz B, Baaske D, Rudlowski C. Foerster R, et al. Among authors: foerster f. Breast Care (Basel). 2014 Apr;9(4):267-71. doi: 10.1159/000365953. Breast Care (Basel). 2014. PMID: 25404886 Free PMC article.
HER2 Low Expression in Primary Male Breast Cancer.
Nobbe K, Erices-Leclercq M, Foerster F, Förster R, Baldus SE, Rudlowski C, Schröder L, Lubig S. Nobbe K, et al. Among authors: foerster f. Breast Cancer (Dove Med Press). 2024 Mar 28;16:141-148. doi: 10.2147/BCTT.S450682. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 38562651 Free PMC article.
Pareto Optimization and Tuning of a Laser Wakefield Accelerator.
Irshad F, Eberle C, Foerster FM, Grafenstein KV, Haberstroh F, Travac E, Weisse N, Karsch S, Döpp A. Irshad F, et al. Among authors: foerster fm. Phys Rev Lett. 2024 Aug 23;133(8):085001. doi: 10.1103/PhysRevLett.133.085001. Phys Rev Lett. 2024. PMID: 39241730
102 results